{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:10:53Z","timestamp":1789474253658,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:00Z","timestamp":1515456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:00Z","timestamp":1515456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>T cell exhaustion occurs during chronic infection and cancers. Programmed cell death protein-1 (PD-1) is a major inhibitory checkpoint receptor involved in T cell exhaustion. Blocking antibodies (Abs) against PD-1 or its ligand, PD-L1, have been shown to reverse T cell exhaustion during chronic infection and cancers, leading to improved control of persistent antigen. However, modeling tumor-specific T cell responses in mouse has been difficult due to the lack of reagents to detect and phenotype tumor-specific immune responses. We developed a novel mouse glioma model expressing a viral epitope derived from lymphocytic choriomeningitis virus (LCMV), which allowed monitoring of tumor-specific CD8 T-cell responses. These CD8 T cells express high levels of PD-1 and are unable to reject tumors, but this can be reversed by anti-PD-1 treatment. These results suggest the efficacy of PD-1 blockade as a treatment for glioblastoma, an aggressive tumor that results in a uniformly lethal outcome. Importantly, this new syngeneic tumor model may also provide further opportunities to characterize anti-tumor T cell exhaustion and develop novel cancer immunotherapies.<\/jats:p>","DOI":"10.1038\/s41598-017-18540-2","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T17:34:17Z","timestamp":1515000857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells"],"prefix":"10.1038","volume":"8","author":[{"given":"Hiroshi","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quazim A.","family":"Alayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Penaloza-MacMaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon J.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Kuchroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Caligiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Antonio","family":"Chiocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,9]]},"reference":[{"key":"18540_CR1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462\u2013477, https:\/\/doi.org\/10.1016\/j.cell.2013.09.034 (2013).","journal-title":"Cell"},{"key":"18540_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682\u2013687, https:\/\/doi.org\/10.1038\/nature04444 (2006).","journal-title":"Nature"},{"key":"18540_CR3","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nri3740","volume":"14","author":"DE Speiser","year":"2014","unstructured":"Speiser, D. E. et al. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol 14, 768\u2013774, https:\/\/doi.org\/10.1038\/nri3740 (2014).","journal-title":"Nat Rev Immunol"},{"key":"18540_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken, K. E. & Wherry, E. J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36, 265\u2013276, https:\/\/doi.org\/10.1016\/j.it.2015.02.008 (2015).","journal-title":"Trends Immunol"},{"key":"18540_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15, 486\u2013499, https:\/\/doi.org\/10.1038\/nri3862 (2015).","journal-title":"Nat Rev Immunol"},{"key":"18540_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.bbi.2012.01.016","volume":"26","author":"T Romo-Gonzalez","year":"2012","unstructured":"Romo-Gonzalez, T., Chavarria, A. & Perez, H. J. Central nervous system: a modified immune surveillance circuit? Brain Behav Immun 26, 823\u2013829, https:\/\/doi.org\/10.1016\/j.bbi.2012.01.016 (2012).","journal-title":"Brain Behav Immun"},{"key":"18540_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nn.3161","volume":"15","author":"SS Ousman","year":"2012","unstructured":"Ousman, S. S. & Kubes, P. Immune surveillance in the central nervous system. Nat Neurosci 15, 1096\u20131101, https:\/\/doi.org\/10.1038\/nn.3161 (2012).","journal-title":"Nat Neurosci"},{"key":"18540_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1126\/science.aag2638","volume":"353","author":"J Kipnis","year":"2016","unstructured":"Kipnis, J. Multifaceted interactions between adaptive immunity and the central nervous system. Science 353, 766\u2013771, https:\/\/doi.org\/10.1126\/science.aag2638 (2016).","journal-title":"Science"},{"key":"18540_CR9","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/neuonc\/nou212","volume":"16","author":"DA Reardon","year":"2014","unstructured":"Reardon, D. A. et al. Immunotherapy advances for glioblastoma. Neuro Oncol 16, 1441\u20131458, https:\/\/doi.org\/10.1093\/neuonc\/nou212 (2014).","journal-title":"Neuro Oncol"},{"key":"18540_CR10","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1158\/1078-0432.CCR-14-0832","volume":"20","author":"PE Fecci","year":"2014","unstructured":"Fecci, P. E., Heimberger, A. B. & Sampson, J. H. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res 20, 5620\u20135629, https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0832 (2014).","journal-title":"Clin Cancer Res"},{"key":"18540_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-015-0371-3","volume":"16","author":"MR Neagu","year":"2015","unstructured":"Neagu, M. R. & Reardon, D. A. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Current treatment options in oncology 16, 54, https:\/\/doi.org\/10.1007\/s11864-015-0371-3 (2015).","journal-title":"Current treatment options in oncology"},{"key":"18540_CR12","doi-asserted-by":"publisher","unstructured":"Tivnan, A., Heilinger, T., Lavelle, E. C. & Prehn, J. H. Advances in immunotherapy for the treatment of glioblastoma. Journal of neuro-oncology, https:\/\/doi.org\/10.1007\/s11060-016-2299-2 (2016).","DOI":"10.1007\/s11060-016-2299-2"},{"key":"18540_CR13","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/2201352a0","volume":"220","author":"I Hellstrom","year":"1968","unstructured":"Hellstrom, I., Hellstrom, K. E., Pierce, G. E. & Yang, J. P. Cellular and humoral immunity to different types of human neoplasms. Nature 220, 1352\u20131354 (1968).","journal-title":"Nature"},{"key":"18540_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1074-7613(00)00026-1","volume":"13","author":"HL Hanson","year":"2000","unstructured":"Hanson, H. L. et al. Eradication of established tumors by CD8+\u2009T cell adoptive immunotherapy. Immunity 13, 265\u2013276 (2000).","journal-title":"Immunity"},{"key":"18540_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bcmd.2007.06.025","volume":"40","author":"S Vuk-Pavlovic","year":"2008","unstructured":"Vuk-Pavlovic, S. Rebuilding immunity in cancer patients. Blood cells, molecules & diseases 40, 94\u2013100, https:\/\/doi.org\/10.1016\/j.bcmd.2007.06.025 (2008).","journal-title":"Blood cells, molecules & diseases"},{"key":"18540_CR16","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","volume":"12","author":"LV Riella","year":"2012","unstructured":"Riella, L. V., Paterson, A. M., Sharpe, A. H. & Chandraker, A. Role of the PD-1 pathway in the immune response. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 12, 2575\u20132587, https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04224.x (2012).","journal-title":"American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"18540_CR17","doi-asserted-by":"publisher","unstructured":"Antonios, J. P. et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1\/PD-L1 mechanism in glioblastoma. Neuro Oncol, https:\/\/doi.org\/10.1093\/neuonc\/now287 (2017).","DOI":"10.1093\/neuonc\/now287"},{"key":"18540_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/nov172","volume":"18","author":"EK Nduom","year":"2016","unstructured":"Nduom, E. K. et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 18, 195\u2013205, https:\/\/doi.org\/10.1093\/neuonc\/nov172 (2016).","journal-title":"Neuro Oncol"},{"key":"18540_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","volume":"4","author":"DA Reardon","year":"2016","unstructured":"Reardon, D. A. et al. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res 4, 124\u2013135, https:\/\/doi.org\/10.1158\/2326-6066.cir-15-0151 (2016).","journal-title":"Cancer Immunol Res"},{"key":"18540_CR20","doi-asserted-by":"publisher","unstructured":"Antonios, J. P. et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight 1, https:\/\/doi.org\/10.1172\/jci.insight.87059 (2016).","DOI":"10.1172\/jci.insight.87059"},{"key":"18540_CR21","doi-asserted-by":"publisher","first-page":"370ra180","DOI":"10.1126\/scitranslmed.aag2942","volume":"8","author":"D Mathios","year":"2016","unstructured":"Mathios, D. et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med 8, 370ra180, https:\/\/doi.org\/10.1126\/scitranslmed.aag2942 (2016).","journal-title":"Sci Transl Med"},{"key":"18540_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","volume":"23","author":"JE Kim","year":"2017","unstructured":"Kim, J. E. et al. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clin Cancer Res 23, 124\u2013136, https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-1535 (2017).","journal-title":"Clin Cancer Res"},{"key":"18540_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fonc.2015.00012","volume":"5","author":"L Ampie","year":"2015","unstructured":"Ampie, L., Woolf, E. C. & Dardis, C. Immunotherapeutic advancements for glioblastoma. Front Oncol 5, 12, https:\/\/doi.org\/10.3389\/fonc.2015.00012 (2015).","journal-title":"Front Oncol"},{"key":"18540_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annual review of immunology 22, 329\u2013360, https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104803 (2004).","journal-title":"Annual review of immunology"},{"key":"18540_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal, D., Gubin, M. M., Schreiber, R. D. & Smyth, M. J. New insights into cancer immunoediting and its three component phases\u2013elimination, equilibrium and escape. Curr Opin Immunol 27, 16\u201325, https:\/\/doi.org\/10.1016\/j.coi.2014.01.004 (2014).","journal-title":"Curr Opin Immunol"},{"key":"18540_CR26","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1172\/JCI80004","volume":"125","author":"MW Teng","year":"2015","unstructured":"Teng, M. W., Galon, J., Fridman, W. H. & Smyth, M. J. From mice to humans: developments in cancer immunoediting. J Clin Invest 125, 3338\u20133346, https:\/\/doi.org\/10.1172\/jci80004 (2015).","journal-title":"J Clin Invest"},{"key":"18540_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fnins.2015.00172","volume":"9","author":"M Deleidi","year":"2015","unstructured":"Deleidi, M., Jaggle, M. & Rubino, G. Immune aging, dysmetabolism, and inflammation in neurological diseases. Front Neurosci 9, 172, https:\/\/doi.org\/10.3389\/fnins.2015.00172 (2015).","journal-title":"Front Neurosci"},{"key":"18540_CR28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1084\/jem.160.2.521","volume":"160","author":"R Ahmed","year":"1984","unstructured":"Ahmed, R., Salmi, A., Butler, L. D., Chiller, J. M. & Oldstone, M. B. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med 160, 521\u2013540 (1984).","journal-title":"J Exp Med"},{"key":"18540_CR29","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.3390\/v4112650","volume":"4","author":"X Zhou","year":"2012","unstructured":"Zhou, X., Ramachandran, S., Mann, M. & Popkin, D. L. Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future. Viruses 4, 2650\u20132669, https:\/\/doi.org\/10.3390\/v4112650 (2012).","journal-title":"Viruses"},{"key":"18540_CR30","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.immuni.2016.10.028","volume":"45","author":"JP Scott-Browne","year":"2016","unstructured":"Scott-Browne, J. P. et al. Dynamic Changes in Chromatin Accessibility Occur in CD8+\u2009T Cells Responding to Viral Infection. Immunity 45, 1327\u20131340, https:\/\/doi.org\/10.1016\/j.immuni.2016.10.028 (2016).","journal-title":"Immunity"},{"key":"18540_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.immuni.2014.01.005","volume":"40","author":"A Crawford","year":"2014","unstructured":"Crawford, A. et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 40, 289\u2013302, https:\/\/doi.org\/10.1016\/j.immuni.2014.01.005 (2014).","journal-title":"Immunity"},{"key":"18540_CR32","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1084\/jem.20132577","volume":"211","author":"P Penaloza-MacMaster","year":"2014","unstructured":"Penaloza-MacMaster, P. et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med 211, 1905\u20131918, https:\/\/doi.org\/10.1084\/jem.20132577 (2014).","journal-title":"J Exp Med"},{"key":"18540_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+\u2009T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421, https:\/\/doi.org\/10.1038\/nature19330 (2016).","journal-title":"Nature"},{"key":"18540_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc.2016.91","volume":"16","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel, L., Pitt, J. M., Daillere, R., Smyth, M. J. & Kroemer, G. Mouse models in oncoimmunology. Nat Rev Cancer 16, 759\u2013773, https:\/\/doi.org\/10.1038\/nrc.2016.91 (2016).","journal-title":"Nat Rev Cancer"},{"key":"18540_CR35","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.cell.2016.08.052","volume":"166","author":"M Singer","year":"2016","unstructured":"Singer, M. et al. A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell 166, 1500\u20131511.e1509, https:\/\/doi.org\/10.1016\/j.cell.2016.08.052 (2016).","journal-title":"Cell"},{"key":"18540_CR36","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.1158\/0008-5472.CAN-13-1550","volume":"73","author":"J Duraiswamy","year":"2013","unstructured":"Duraiswamy, J., Freeman, G. J. & Coukos, G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 73, 6900\u20136912, https:\/\/doi.org\/10.1158\/0008-5472.can-13-1550 (2013).","journal-title":"Cancer Res"},{"key":"18540_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-107","volume":"12","author":"T Oh","year":"2014","unstructured":"Oh, T. et al. Immunocompetent murine models for the study of glioblastoma immunotherapy. J Transl Med 12, 107, https:\/\/doi.org\/10.1186\/1479-5876-12-107 (2014).","journal-title":"J Transl Med"},{"key":"18540_CR38","doi-asserted-by":"publisher","unstructured":"Chamberlain, M. C. & Kim, B. T. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. Journal of neuro-oncology, https:\/\/doi.org\/10.1007\/s11060-017-2466-0 (2017).","DOI":"10.1007\/s11060-017-2466-0"},{"key":"18540_CR39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1084\/jem.20001021","volume":"195","author":"JN Blattman","year":"2002","unstructured":"Blattman, J. N. et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med 195, 657\u2013664 (2002).","journal-title":"J Exp Med"},{"key":"18540_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.immuni.2015.12.018","volume":"44","author":"N Malandro","year":"2016","unstructured":"Malandro, N. et al. Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. Immunity 44, 179\u2013193, https:\/\/doi.org\/10.1016\/j.immuni.2015.12.018 (2016).","journal-title":"Immunity"},{"key":"18540_CR41","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/eji.200323800","volume":"33","author":"L Klein","year":"2003","unstructured":"Klein, L. et al. Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor. Eur J Immunol 33, 806\u2013814, https:\/\/doi.org\/10.1002\/eji.200323800 (2003).","journal-title":"Eur J Immunol"},{"key":"18540_CR42","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20142237","volume":"212","author":"PM Odorizzi","year":"2015","unstructured":"Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A. & Wherry, E. J. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+\u2009T cells. J Exp Med 212, 1125\u20131137, https:\/\/doi.org\/10.1084\/jem.20142237 (2015).","journal-title":"J Exp Med"},{"key":"18540_CR43","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3389\/fimmu.2015.00310","volume":"6","author":"SA Fuertes Marraco","year":"2015","unstructured":"Fuertes Marraco, S. A., Neubert, N. J., Verdeil, G. & Speiser, D. E. Inhibitory Receptors Beyond T Cell Exhaustion. Front Immunol 6, 310, https:\/\/doi.org\/10.3389\/fimmu.2015.00310 (2015).","journal-title":"Front Immunol"},{"key":"18540_CR44","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1126\/science.aae0491","volume":"354","author":"DR Sen","year":"2016","unstructured":"Sen, D. R. et al. The epigenetic landscape of T cell exhaustion. Science 354, 1165\u20131169, https:\/\/doi.org\/10.1126\/science.aae0491 (2016).","journal-title":"Science"},{"key":"18540_CR45","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.coi.2010.03.007","volume":"22","author":"KE Brown","year":"2010","unstructured":"Brown, K. E., Freeman, G. J., Wherry, E. J. & Sharpe, A. H. Role of PD-1 in regulating acute infections. Curr Opin Immunol 22, 397\u2013401, https:\/\/doi.org\/10.1016\/j.coi.2010.03.007 (2010).","journal-title":"Curr Opin Immunol"},{"key":"18540_CR46","doi-asserted-by":"publisher","first-page":"6280","DOI":"10.4049\/jimmunol.1003870","volume":"186","author":"SR Allie","year":"2011","unstructured":"Allie, S. R., Zhang, W., Fuse, S. & Usherwood, E. J. Programmed death 1 regulates development of central memory CD8 T cells after acute viral infection. J Immunol 186, 6280\u20136286, https:\/\/doi.org\/10.4049\/jimmunol.1003870 (2011).","journal-title":"J Immunol"},{"key":"18540_CR47","doi-asserted-by":"publisher","unstructured":"Dronca, R. S. et al. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight 1, https:\/\/doi.org\/10.1172\/jci.insight.86014 (2016).","DOI":"10.1172\/jci.insight.86014"},{"key":"18540_CR48","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/neuonc\/now002","volume":"18","author":"LA Wheeler","year":"2016","unstructured":"Wheeler, L. A. et al. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro Oncol 18, 1137\u20131145, https:\/\/doi.org\/10.1093\/neuonc\/now002 (2016).","journal-title":"Neuro Oncol"},{"key":"18540_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.12.011","volume":"130","author":"D Mangani","year":"2017","unstructured":"Mangani, D., Weller, M. & Roth, P. The network of immunosuppressive pathways in glioblastoma. Biochemical pharmacology 130, 1\u20139, https:\/\/doi.org\/10.1016\/j.bcp.2016.12.011 (2017).","journal-title":"Biochemical pharmacology"},{"key":"18540_CR50","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst, A. O. et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355, 1423\u20131427, https:\/\/doi.org\/10.1126\/science.aaf0683 (2017).","journal-title":"Science"},{"key":"18540_CR51","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160\u20131165, https:\/\/doi.org\/10.1126\/science.aaf2807 (2016).","journal-title":"Science"},{"key":"18540_CR52","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/ni.2606","volume":"14","author":"DT Utzschneider","year":"2013","unstructured":"Utzschneider, D. T. et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol 14, 603\u2013610, https:\/\/doi.org\/10.1038\/ni.2606 (2013).","journal-title":"Nat Immunol"},{"key":"18540_CR53","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nature13387","volume":"512","author":"T Schumacher","year":"2014","unstructured":"Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324\u2013327, https:\/\/doi.org\/10.1038\/nature13387 (2014).","journal-title":"Nature"},{"key":"18540_CR54","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow, J. E. et al. Glioma Groups Based on 1p\/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med 372, 2499\u20132508, https:\/\/doi.org\/10.1056\/NEJMoa1407279 (2015).","journal-title":"N Engl J Med"},{"key":"18540_CR55","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry, E. J. et al. Molecular signature of CD8+\u2009T cell exhaustion during chronic viral infection. Immunity 27, 670\u2013684, https:\/\/doi.org\/10.1016\/j.immuni.2007.09.006 (2007).","journal-title":"Immunity"},{"key":"18540_CR56","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.15252\/embj.201490786","volume":"34","author":"M Giordano","year":"2015","unstructured":"Giordano, M. et al. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. Embo j 34, 2042\u20132058, https:\/\/doi.org\/10.15252\/embj.201490786 (2015).","journal-title":"Embo j"},{"key":"18540_CR57","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1074\/jbc.M114.593871","volume":"290","author":"H Nakashima","year":"2015","unstructured":"Nakashima, H., Nguyen, T., Goins, W. F. & Chiocca, E. A. Interferon-stimulated gene 15 (ISG15) and ISG15-linked proteins can associate with members of the selective autophagic process, histone deacetylase 6 (HDAC6) and SQSTM1\/p62. J Biol Chem 290, 1485\u20131495, https:\/\/doi.org\/10.1074\/jbc.M114.593871 (2015).","journal-title":"J Biol Chem"},{"key":"18540_CR58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/BF03159989","volume":"17","author":"TN Seyfried","year":"1992","unstructured":"Seyfried, T. N., el-Abbadi, M. & Roy, M. L. Ganglioside distribution in murine neural tumors. Molecular and chemical neuropathology 17, 147\u2013167 (1992).","journal-title":"Molecular and chemical neuropathology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18540-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18540-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18540-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T01:49:18Z","timestamp":1671846558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18540-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,9]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["18540"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-18540-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,9]]},"assertion":[{"value":"15 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.F. has patents\/pending royalties on the PD-1 pathway. Other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"208"}}